Lineage Cell Therapeutics, Inc. (LCTX) Operating income 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual operating income history from SEC filings — each fiscal year as reported.
-$36.6MFY2025 · since FY2016: -$59.0M → -$36.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$36.6M | -70.5% |
| FY2024 | -$21.5M | +13.2% |
| FY2023 | -$24.7M | -9.8% |
| FY2022 | -$22.5M | +54.2% |
| FY2021 | -$49.2M | -86.1% |
| FY2020 | -$26.4M | +32.0% |
| FY2019 | -$38.9M | +7.0% |
| FY2018 | -$41.8M | -7.4% |
| FY2017 | -$38.9M | +34.0% |
| FY2016 | -$59.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice